Privo Technologies Inc

Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avoids stomach acids, can significantly reduce toxic side effects of drugs and allows for higher dosing where the drugs can be most effective all of which improve patient outcomes and compliance. Privo was founded by Manijeh Goldberg who is a seasoned executive with...

Nanotechnology,oncology,oral cancer,buccal drug-delivery,treatment-targeting,immunogenesis,immunomodulation,intraoperative chemotherapy,intraoperative therapy,mucosal cancers,vaginal cancer,and rectal cancer

Privo technologies inc operates in the Biotechnology research industry.

Privo technologies inc's revenue is 11m - 100m

Privo technologies inc has 11 - 50 employees.